In terms of other secondary efficacy indicators, including lipid, blood glucose and insulin levels, inflammatory cytokines, and obesity parameter, there were no significant differences between the placebo and ZSP1601 treatment groups at the end of treatment, compared to baseline. This evidence concerns the gene INS and Obesity.